FDA Proposes Rule to Streamline Distributed Manufacturing Registration and Close Foreign API Supply Chain Gaps
核心洞察
The FDA proposed a rule allowing distributed manufacturing "hub-and-spoke" models to register as a single establishment, reducing administrative burdens and costs.
Foreign establishments manufacturing APIs that indirectly enter the U.S. supply chain would be required to register with the FDA under the proposed rule.
The changes aim to enhance supply chain transparency and give the FDA real-time oversight into where and how drugs are manufactured.
The U.S. Food and Drug Administration on July 10, 2026 issued a proposed rule that would modernize drug manufacturing establishment registration, creating a streamlined pathway for distributed manufacturing operations and closing a longstanding gap in foreign supply chain visibility. The proposal, announced from Silver Spring, MD, represents the latest in a series of administration actions aimed at revitalizing American pharmaceutical manufacturing and reducing vulnerabilities in the drug supply chain.
"If finalized, the proposed rule is expected to reduce registration costs for distributed manufacturing companies and generate long-term efficiencies for both industry and the agency," the FDA stated.
A Single Registration for Hub-and-Spoke Networks
Under current regulations, distributed manufacturing establishments operating under a "hub-and-spoke" model—where a central quality oversight hub coordinates multiple equivalent manufacturing units across different locations—must register each unit as a separate establishment. The FDA acknowledged that this requirement is "unnecessarily burdensome" for the industry and could hinder the adoption and implementation of distributed manufacturing.
The proposed rule would allow these networks to register as a single establishment. Units could be added, relocated, or removed through a streamlined update process, and companies would be required to notify the FDA in advance of any unit relocation, closing a gap in the agency's real-time oversight.
"The FDA is proposing changes to our establishment registration regulations that would reflect how distributed manufacturing actually works — as one single establishment," said Michael Davis, M.D., Ph.D., Acting Director of FDA's Center for Drug Evaluation and Research (CDER). "The proposed changes would make it easier for innovative manufacturers to operate efficiently, and give the FDA a clearer, more accurate picture of how and where drugs are being made."
The FDA defines a distributed manufacturing model as a decentralized production strategy where a core manufacturing platform—consisting of raw materials, software, and equipment—is deployed across multiple manufacturing units at various locations. The agency noted that it considered comments from a discussion paper released in October 2022 in developing the proposed rule, which had posed questions related to the technical aspects of distributed manufacturing technologies and compliance with good manufacturing practices.
Closing the Foreign API Registration Gap
The proposed rule also clarifies registration and drug listing requirements for certain foreign drug manufacturing establishments. Currently, some foreign establishments that manufacture drugs—including active pharmaceutical ingredients (APIs)—only for distribution to other foreign establishments may not be registered with the FDA, limiting the agency's visibility into upstream supply chains.
This change aligns FDA regulations with Section 2511 of the PREVENT Pandemics Act, which amended section 510(i) of the Federal Food, Drug, and Cosmetic Act to require the registration of foreign establishments engaged in the manufacturing or processing of a drug that is imported into the U.S., regardless of whether the drug undergoes further manufacturing at a different location outside the U.S.
"When an active ingredient in a medicine reaches an American patient, the FDA should be able to trace exactly where it came from," said Davis. "Closing this registration gap for foreign establishments is a concrete step toward increasing the supply chain transparency that patients deserve."
The FDA said this change is designed to give the agency greater visibility into upstream manufacturing activities, enhancing its ability to identify and address potential supply chain risks and detect and respond to potential safety concerns.
Broader Impact
The proposed rule builds on a series of administration actions aimed at revitalizing American pharmaceutical manufacturing, improving supply chain transparency, and reducing vulnerabilities in the drug supply chain. If finalized, it is expected to reduce registration costs for distributed manufacturing companies and generate long-term efficiencies for both industry and the agency, while ensuring that regulatory frameworks keep pace with innovation.